The RET protooncogene

Cancer Treatment and Research

Volumn 153, Issue , 2010, Pages 303-319

  Moley, Jeffrey F ^a   Traugott, Amber L ^b  

^a USA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHOTRANSFERASE; PROTEIN RET;

CELL DIFFERENTIATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KIDNEY AGENESIS; LYMPHOMA; NEUROFIBROMATOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SIPPLE SYNDROME; THYROID CARCINOMA;

GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; THYROID NEOPLASMS;

EID: 77953671077     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0857-5_17     Document Type: Review

References (114)

1. Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581-588
2. Ishizaka Y, Itoh F, Tahira T et al. (1989) Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4:1519-1521
3. Baloh RH, Tansey MG, Lampe PA et al. (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21:1291-1302
4. Kotzbauer PT, Lampe PA, Heuckeroth RO et al. (1996) Neurturin, a relative of glial-cell-linederived neurotrophic factor. Nature 384:467-470
5. Milbrandt J, De Sauvage FJ, Fahrner TJ et al. (1998) Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20:245-253
6. Treanor JJ, Goodman L, De Sauvage F et al. (1996) Characterization of a multicomponent receptor for GDNF. Nature 382:80-83
7. Trupp M, Arenas E, Fainzilber M et al. (1996) Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 381:785-789
8. Runeberg-Roos P, Saarma M (2007) Neurotrophic factor receptor RET: Structure, cell biology, and inherited diseases. Ann Med 39:572-580
9. Jing S, Wen D, Yu Y et al. (1996) GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85:1113-1124
10. Amoresano A, Incoronato M, Monti G, Pucci P, De Franciscis V, Cerchia L (2005) Direct interactions among Ret, GDNF and GFRalpha1 molecules reveal new insights into the assembly of a functional three-protein complex. Cell Signal 17:717-727
11. Kjaer S, Ibanez CF (2003) Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET. J Biol Chem 278:47898-47904
12. Freche B, Guillaumot P, Charmetant J et al. (2005) Inducible dimerization of RET reveals a specific AKT deregulation in oncogenic signaling. J Biol Chem 280:36584-36591
13. Paratcha G, Ledda F, Baars L et al. (2001) Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts. Neuron 29:171-184
14. Tansey MG, Baloh RH, Milbrandt J, Johnson EM Jr (2000) GFRalpha-mediated localization of RET to lipid rafts is required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25:611-623
15. Lucero HA, Robbins PW (2004) Lipid rafts-protein association and the regulation of protein activity. Arch Biochem Biophys 426:208-224
16. Pierchala BA, Milbrandt J, Johnson EM Jr (2006) Glial cell line-derived neurotrophic factordependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation. J Neurosci 26:2777-2787
17. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 28:39-49
18. Donatello S, Fiorino A, Degl'Innocenti D et al. (2007) SH2B1beta adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene 26:6546-6559
19. Alberti L, Borrello MG, Ghizzoni S, Torriti F, Rizzetti MG, Pierotti MA (1998) Grb2 binding to the different isoforms of Ret tyrosine kinase. Oncogene 17:1079-1087
20. Arighi E, Alberti L, Torriti F et al. (1997) Identification of Shc docking site on Ret tyrosine kinase. Oncogene 14:773-782
21. Asai N, Murakami H, Iwashita T, Takahashi M (1996) A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins. J Biol Chem 271:17644-17649
22. De Vita G, Melillo RM, Carlomagno F et al. (2000) Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res 60:3727-3731
23. Degl'Innocenti D, Arighi E, Popsueva A et al. (2004) Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching. Oncogene 23:7297-7309
24. Encinas M, Crowder RJ, Milbrandt J, Johnson EM Jr (2004) Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. J Biol Chem 279:18262-18269
25. Hayashi H, Ichihara M, Iwashita T et al. (2000) Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19:4469-4475
26. Hayashi Y, Iwashita T, Murakamai H et al. (2001) Activation of BMK1 via tyrosine 1062 in RET by GDNF and MEN2A mutation. Biochem Biophys Res Commun 281:682-689
27. Iwashita T, Asai N, Murakami H, Matsuyama M, Takahashi M (1996) Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation. Oncogene 12:481-487
28. Kurokawa K, Iwashita T, Murakami H, Hayashi H, Kawai K, Takahashi M (2001) Identification of SNT/FRS2 docking site on RET receptor tyrosine kinase and its role for signal transduction. Oncogene 20:1929-1938
29. Lopez-Ramirez MA, Dominguez-Monzon G, Vergara P, Segovia J (2008) Gas1 reduces Ret tyrosine 1062 phosphorylation and alters GDNF-mediated intracellular signaling. Int J Dev Neurosci 26:497-503
30. Pandey A, Duan H, Di Fiore PP, Dixit VM (1995) The Ret receptor protein tyrosine kinase associates with the SH2-containing adapter protein Grb10. J Biol Chem 270:21461-21463
31. Pandey A, Liu X, Dixon JE, Di Fiore PP, Dixit VM (1996) Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7. J Biol Chem 271:10607-10610
32. Salvatore D, Barone MV, Salvatore G et al. (2000) Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. J Clin Endocrinol Metab 85: 3898-3907
33. Wong A, Bogni S, Kotka P et al. (2005) Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform. Mol Cell Biol 25:9661-9673
34. Coulpier M, Anders J, Ibanez CF (2002) Coordinated activation of autophosphorylation sites in the RET receptor tyrosine kinase: Importance of tyrosine 1062 for GDNF mediated neuronal differentiation and survival. J Biol Chem 277:1991-1999
35. Kawamoto Y, Takeda K, Okuno Y et al. (2004) Identification of RET autophosphorylation sites by mass spectrometry. J Biol Chem 279:14213-14224
36. Arighi E, Borrello MG, Sariola H (2005) RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16:441-467
37. Trupp M, Scott R, Whittemore SR, Ibanez CF (1999) Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 274:20885-20894
38. van Weering DH, Medema JP, van Puijenbroek A, Burgering BM, Baas PD, Bos JL (1995) Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells. Oncogene 11:2207-2214 (Pubitemid 26008396)
39. Borrello MG, Alberti L, Arighi E et al. (1996) The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 16:2151-2163
40. Chiariello M, Visconti R, Carlomagno F et al. (1998) Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): Evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene 16:2435-2445
41. Fukuda T, Kiuchi K, Takahashi M (2002) Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J Biol Chem 277:19114-19121
42. Asai N, Fukuda T, Wu Z et al. (2006) Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. Development 133:4507-4516
43. Lee RH, Wong WL, Chan CH, Chan SY (2006) Differential effects of glial cell line-derived neurotrophic factor and neurturin in RET/GFRalpha1-expressing cells. J Neurosci Res 83:80-90
44. Parkash V, Leppanen VM, Virtanen H et al. (2008) The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: Insights into RET signaling and heparin binding. J Biol Chem 283:35164-35172
45. Borrello MG, Mercalli E, Perego C et al. (2002) Differential interaction of Enigma protein with the two RET isoforms. Biochem Biophys Res Commun 296:515-522
46. Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J, Johnson EM Jr (2002) The long and short isoforms of Ret function as independent signaling complexes. J Biol Chem 277: 34618-34625
47. Schuetz G, Rosario M, Grimm J, Boeckers TM, Gundelfinger ED, Birchmeier W (2004) The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells. J Cell Biol 167:945-952
48. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V (1994) Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380-383
49. De Graaff E, Srinivas S, Kilkenny C et al. (2001) Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15:2433-2444
50. Srinivas S, Wu Z, Chen CM, D'Agati V, Costantini F (1999) Dominant effects of RET receptor misexpression and ligand-independent RET signaling on ureteric bud development. Development 126:1375-1386
51. Lee DC, Chan KW, Chan SY (2002) RET receptor tyrosine kinase isoforms in kidney function and disease. Oncogene 21:5582-5592
52. Pichel JG, Shen L, Sheng HZ et al. (1996) Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382:73-76
53. Schuchardt A, D'Agati V, Pachnis V, Costantini F (1996) Renal agenesis and hypodysplasia in ret-k- mutant mice result from defects in ureteric bud development. Development 122:1919-1929
54. Enomoto H, Araki T, Jackman A et al. (1998) GFR alpha1-deficient mice have deficits in the enteric nervous system and kidneys. Neuron 21:317-324
55. Enomoto H, Heuckeroth RO, Golden JP, Johnson EM, Milbrandt J (2000) Development of cranial parasympathetic ganglia requires sequential actions of GDNF and neurturin. Development 127:4877-4889
56. Taraviras S, Marcos-Gutierrez CV, Durbec P et al. (1999) Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system. Development 126:2785-2797
57. Veiga-Fernandes H, Coles MC, Foster KE et al. (2007) Tyrosine kinase receptor RET is a key regulator of Peyer's patch organogenesis. Nature 446:547-551
58. Marcos C, Pachnis V (1996) The effect of the ret- mutation on the normal development of the central and parasympathetic nervous systems. Int J Dev Biol Suppl. 1:137S-138S
59. Donis-Keller H, Dou S, Chi D et al. (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856
60. Mulligan LM, Kwok JB, Healey CS et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460
61. Carlson KM, Dou S, Chi D et al. (1994) Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91:1579-1583
62. Brandi ML, Gagel RF, Angeli A et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
63. Miller CA, Ellison EC (2005) Multiple Endocrine Neoplasia Type 2B. In: Clark OH, Duh Q-Y, Kebebew E (eds) Textbook of endocrine surgery, 2nd edn. W.B. Saunders, Philadelphia, pp 757-763
64. Eng C, Clayton D, Schuffenecker I et al. (1996) The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579
65. Frank-Raue K, Hoppner W, Frilling A et al. (1996) Mutations of the ret protooncogene in German multiple endocrine neoplasia families: Relation between genotype and phenotype. German medullary thyroid carcinoma study group. J Clin Endocrinol Metab 81:1780-1783
66. Quayle FJ, Fialkowski EA, Benveniste R, Moley JF (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800-805 Discussion 5 e1
67. Rodriguez JM, Balsalobre M, Ponce JL et al. (2008) Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J Surg 32:2520-2526
68. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999-4003
69. Howe JR, Norton JA, Wells SA Jr (1993) Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up. Surgery 114:1070-1077
70. Kraimps JL, Denizot A, Carnaille B et al. (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: Retrospective French multicentric study. Groupe d'EtuDe des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20:808-812 Discussion 12-13
71. Herfarth KK, Bartsch D, Doherty GM, Wells SA Jr, Lairmore TC (1996) Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Surgery 120:966-973 Discussion 73-74
72. Schuffenecker I, Virally-Monod M, Brohet R et al. (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etuDe des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83:487-491
73. Miyauchi A, Futami H, Hai N et al. (1999) Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res 90:1-5
74. Gujral TS, Singh VK, Jia Z, Mulligan LM (2006) Molecular mechanisms of RET receptormediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 66:10741-10749
75. Santoro M, Carlomagno F, Romano A et al. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267:381-383
76. Bongarzone I, Vigano E, Alberti L et al. (1998) Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene 16:2295-2301
77. Songyang Z, Carraway KL 3rd, Eck MJ et al. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373:536-539
78. Bocciardi R, Mograbi B, Pasini B et al. (1997) The multiple endocrine neoplasia type 2B point mutation switches the specificity of the Ret tyrosine kinase towards cellular substrates that are susceptible to interact with Crk and Nck. Oncogene 15:2257-2265
79. Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE (1996) Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities. J Biol Chem 271:5309-5312
80. Murakami H, Iwashita T, Asai N et al. (1999) Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation. Biochem Biophys Res Commun 262:68-75
81. Asai N, Iwashita T, Matsuyama M, Takahashi M (1995) Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15:1613-1619
82. Kjaer S, Kurokawa K, Perrinjaquet M, Abrescia C, Ibanez CF (2006) Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations. Oncogene 25:7086-7095
83. D'Aloiso L, Carlomagno F, Bisceglia M et al. (2006) Clinical case seminar: In vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. J Clin Endocrinol Metab 91:754-759
84. Jimenez C, Dang GT, Schultz PN et al. (2004) A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89:3521-3526
85. Pigny P, Bauters C, Wemeau JL et al. (1999) A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma. J Clin Endocrinol Metab 84:1700-1704
86. Ercolino T, Lombardi A, Becherini L et al. (2008) The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol (Oxf) 69:253-258
87. Machens A, Dralle H (2007) Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31:957-968
88. Elisei R, Cosci B, Romei C et al. (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 93:682-687
89. Marsh DJ, Learoyd DL, Andrew SD et al. (1996) Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 44:249-257
90. Zedenius J, Larsson C, Bergholm U et al. (1995) Mutations of codon 918 in the RET protooncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80:3088-3090
91. Schilling T, Burck J, Sinn HP et al. (2001) Prognostic value of codon 918 (ATG- > ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66
92. Eng C, Mulligan LM, Healey CS et al. (1996) Heterogeneous mutation of the RET protooncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 56:2167-2170 (Pubitemid 26119920)
93. Ciampi R, Giordano TJ, Wikenheiser-Brokamp K, Koenig RJ, Nikiforov YE (2007) HOOK3-RET: A novel type of RET/PTC rearrangement in papillary thyroid carcinoma. Endocr Relat Cancer 14:445-452
94. Santoro M, Melillo RM, Fusco A (2006) RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol 155:645-653
95. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE (2006) Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: Effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91:3603-3610
96. Bounacer A, Wicker R, Caillou B et al. (1997) High prevalence of activating ret protooncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 15:1263-1273
97. Collins BJ, Chiappetta G, Schneider AB et al. (2002) RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J Clin Endocrinol Metab 87:3941-3946
98. Fugazzola L, Pilotti S, Pinchera A et al. (1995) Oncogenic rearrangements of the RET protooncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 55:5617-5620
99. Ito T, Seyama T, Iwamoto KS et al. (1994) Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 344:259
100. Klugbauer S, Jauch A, Lengfelder E, Demidchik E, Rabes HM (2000) A novel type of RET rearrangement (PTC8) in childhood papillary thyroid carcinomas and characterization of the involved gene (RFG8). Cancer Res 60:7028-7032
101. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA (1997) Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694
102. Rabes HM, Demidchik EP, Sidorow JD et al. (2000) Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: Biological, phenotypic, and clinical implications. Clin Cancer Res 6:1093-1103
103. Alipov G, Ito M, Prouglo Y, Takamura N, Yamashita S (1999) Ret proto-oncogene rearrangement in thyroid cancer around Semipalatinsk nuclear testing site. Lancet 354:1528-1529
104. Thomas GA, Bunnell H, Cook HA et al. (1999) High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: A strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 84:4232-4238
105. Ito T, Seyama T, Iwamoto KS et al. (1993) In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 53:2940-2943
106. Mizuno T, Iwamoto KS, Kyoizumi S et al. (2000) Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 19:438-443
107. Mizuno T, Kyoizumi S, Suzuki T, Iwamoto KS, Seyama T (1997) Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 15:1455-1460
108. Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D (1998) Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol 153:1443-1450
109. Carlomagno F, Anaganti S, Guida T et al. (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334
110. Carlomagno F, Vitagliano D, Guida T et al. (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
111. Cohen MS, Hussain HB, Moley JF (2002) Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960-966 Discussion 6-7
112. De Groot JW, Plaza Menacho I, Schepers H et al. (2006) Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 139:806-814
113. Kim DW, Jo YS, Jung HS et al. (2006) An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076
114. Marsee DK, Venkateswaran A, Tao H et al. (2004) Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodiDe accumulation in thyroid cells. J Biol Chem 279:43990-43997